Watch List for Investors: Demandware, Inc., Charter Financial Corporation (NASDAQ:CHFN), ZIOPHARM Oncology (NASDAQ:ZIOP), InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV)

LyondellBasell Industries N.V. (NYSE:LYB) shares moved up 0.76% in last trading session and ended the day at $93.62. LYB Gross Margin is 19.70% and its has a return on assets of 18.40%. LyondellBasell Industries N.V. (NYSE:LYB) quarterly performance is 3.21%.

LyondellBasell (NYSE:LYB), one of the world’s largest plastics, chemical and refining companies, announced that Doug Pike, vice president, Investor Relations, will address investors at 10:15 a.m. EDT on November 9, 2015, during the Morgan Stanley Global Chemicals and Agriculture Conference at the Intercontinental Boston hotel, located at 510 Atlantic Avenue.

Demandware, Inc. (NYSE:DWRE) ended the last trading day at $56.12. Company weekly volatility is calculated as 3.26% and price to cash ratio as 11.31. Demandware, Inc. (NYSE:DWRE) showed a weekly performance of -1.46%.

Demandware (NYSE: DWRE) reported Q3 EPS of $0.07, $0.16 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $57.6 million versus the consensus estimate of $53.48 million. Lowers outlook.

On 02 November, Charter Financial Corporation (NASDAQ:CHFN) shares moved up 1.22% and was closed at $13.26. CHFN EPS growth in last 5 year was 22.90%. Charter Financial Corporation (NASDAQ:CHFN) year to date (YTD) performance is 15.81%.

Charter Financial Corporation (NASDAQ:CHFN) announced that its board of directors has declared a regular quarterly cash dividend of $0.05 per share. The dividend is payable on November 24, 2015, to stockholders of record as of November 10, 2015.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) shares moved up 7.55% in last trading session and ended the day at $12.25. ZIOP has a return on assets of -124.50%. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) quarterly performance is -8.58%.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) reported Net loss for the third quarter of 2015 was $18.2 million, or $(0.14) per share, compared to a net loss of $6.1 million, or $(0.06) per share, for the third quarter of 2014. Included in the loss for the third quarter of 2014 was non-cash income of $5.8 million, or $(0.06) per share for the change in fair value of warrants.

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) caters to the Healthcare space. Its weekly performance is 0.38%. On the last day of trading company shares ended up at $7.90. InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) distance from 50-day simple moving average (SMA50) is 3.53%.

On 23 October, InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) announced a 12-month post-implant update for the first study patient in the company’s ongoing pilot trial of its investigational Neuro-Spinal Scaffold™ in patients with complete acute spinal cord injury.